Insider Trading March 6, 2026

Phinia VP Disposes $277K in Shares; Company Posts Mixed Q4 2025 Results

Operational excellence executive sells 3,812 shares as Phinia reports revenue beat but EPS shortfall; stock trading below sale price yet higher year-over-year

By Marcus Reed PHIN
Phinia VP Disposes $277K in Shares; Company Posts Mixed Q4 2025 Results
PHIN

Christopher Gustanski, Phinia Inc.'s vice president of Operational Excellence, sold 3,812 shares of common stock on March 4, 2026, in a transaction valued at $277,239. The sale came as Phinia reported fourth-quarter 2025 results that beat on revenue but missed on earnings per share. At the time of reporting, the company's share price was lower than the sale price but up roughly 60% over the prior year. Third-party analysis cited in filings indicates the stock may be slightly undervalued on a Fair Value basis and shows a low PEG ratio.

Key Points

  • Insider sale: Christopher Gustanski sold 3,812 shares on March 4, 2026, for $72.728 per share, totaling $277,239.
  • Post-sale holdings: Gustanski retains 14,871 shares, including 6,744 restricted shares.
  • Quarterly results: Q4 2025 EPS was $1.18 (missed $1.22 forecast by 3.28%), while revenue was $889 million (beat $838 million forecast by 6.09%).

Christopher Gustanski, who serves as vice president of Operational Excellence at Phinia Inc. (NYSE:PHIN), completed a sale of 3,812 shares of the company's common stock on March 4, 2026, according to a Form 4 submitted to the Securities and Exchange Commission.

The shares changed hands at $72.728 apiece, producing a gross transaction value of $277,239. After the disposition, Gustanski is listed as directly holding 14,871 shares of Phinia, of which 6,744 are identified as restricted stock.

At the time of publication, Phinia's market quote stood at $67.22 per share - below the price at which Gustanski sold but representing approximately a 60% increase compared with the stock's level a year earlier. An InvestingPro assessment referenced in regulatory filings describes the shares as appearing slightly undervalued when measured against a Fair Value estimate and classifies PHIN among names on a Most Undervalued list. The same analysis highlights a price/earnings-to-growth (PEG) ratio of 0.24 for the company. The filing also notes that InvestingPro provides 10 additional exclusive tips for PHIN investors.

Separately, Phinia disclosed fourth-quarter results for 2025 that presented a mixed financial picture. Reported earnings per share for the quarter were $1.18, below the $1.22 forecast and representing a 3.28% negative surprise relative to analysts' expectations. Revenue for the quarter totaled $889 million, surpassing the $838 million consensus and producing a 6.09% positive surprise.

The combination of a revenue beat alongside an EPS miss framed the quarter as one where top-line strength offset a shortfall in per-share profitability. Company disclosures indicated investor interest in the company's strategic initiatives, reflected in resilient activity in pre-market trading after the results were posted. Those market reactions, according to the filing, underscore how revenue performance can influence investor sentiment even when EPS falls short.

This regulatory filing and the company's reported quarterly metrics together form the most recent public developments surrounding insider activity and financial performance at Phinia. The Form 4 provides the precise transaction details for Gustanski's sale; the earnings release supplies the comparable quarter-by-quarter outcomes for Q4 2025.

Risks

  • Earnings shortfall: The EPS miss for Q4 2025 represents an immediate uncertainty for profitability metrics and could affect investor sentiment in the short term - impacting equity markets and investor allocations.
  • Insider selling: The disclosure of a sizeable insider sale may raise questions among shareholders about near-term insider confidence, which can influence market perception and trading behavior in the stock.
  • Market price divergence: The stock is trading below the insider sale price, creating potential valuation and timing uncertainties for investors considering entry or exit - relevant to equity and portfolio managers.

More from Insider Trading

BrightSpring Health Executive Disposes $1.23M in BTSG Stock Amid Active Analyst Coverage Mar 6, 2026 Innospec Director Disposes of $45K in Stock; Form 4/A Corrects Reported Price Mar 6, 2026 QuantumScape CTO Disposes $1.1 Million in Shares as Company Navigates Production and Market Headwinds Mar 6, 2026 Director Sells Small Stake as Sera Prognostics Posts Strong Clinical Trial Results Mar 6, 2026 Bicara CEO Disposes $154,324 of BCAX Shares After Option Exercise Mar 6, 2026